**Supplemental Table S7.** Allele Frequencies of HLA-DQB1 in Patients with ICI-T1DM

| Allele | ICI-T1DM (n=14) | | | | | ICI-controls (n=26) | | | Controls (n=1,483)[a] | ICI-T1DM vs. ICI-controls | ICI-controls vs. controls |
|---|---|---|---|---|---|---|---|---|---|---|---|
| | Number | F, % | P value[b] | OR | 95% CI | Number | F, % | P value[b] | F, % | P value[b] | P value[b] |
| DQB1*03:01 | 1 | 7.1 | NS | | | 0 | 0.0 | NS | 11.43 | NS | NS |
| DQB1*03:02 | 2 | 14.3 | NS | | | 4 | 15.4 | NS | 9.59 | NS | NS |
| DQB1*03:03 | 2 | 14.3 | NS | | | 5 | 19.2 | NS | 15.54 | NS | NS |
| DQB1*04:01 | 5 | 35.7 | 0.045[c] | 3.72 | 1.08–12.83 | 4 | 15.4 | NS | 12.90 | NS | NS |
| DQB1*04:02 | 0 | 0 | NS | | | 1 | 3.8 | NS | 4.21 | NS | NS |
| DQB1*05:01 | 0 | 0 | NS | | | 1 | 3.8 | NS | 6.58 | NS | NS |
| DQB1*05:02 | 0 | 0 | NS | | | 0 | 0.0 | NS | 2.64 | NS | NS |
| DQB1*05:03 | 1 | 7.1 | NS | | | 1 | 3.8 | NS | 3.94 | NS | NS |
| DQB1*06:01 | 3 | 21.4 | NS | | | 3 | 11.5 | NS | 19.08 | NS | NS |
| DQB1*06:02 | 0 | 0 | NS | | | 5 | 19.2 | NS | 7.15 | NS | NS |
| DQB1*06:04 | 0 | 0 | NS | | | 2 | 7.7 | NS | 5.18 | NS | NS |
| Others | 0 | 0 | NS | | | 0 | 0.0 | NS | 1.76 | NS | NS |
| Total | 14 | 100.00 | | | | 26 | 72.22 | | 100.00 | | |

Alleles with frequencies more than 1.0% in controls were included to the analysis (11 alleles).

HLA-DQB1, human leukocyte antigen DQB1; ICI-T1DM, immune-checkpoint inhibitor-induced type 1 diabetes mellitus; F, frequency of the allele; OR, odds ratio; CI, confidence interval; NS, not significant.

[a]Control subjects: Japanese Society for Histocompatibility and Immunogenetics (http://jshi.umin.ac.jp/standarization/file/JSHI-hyokiallele-2021list.pdf) (JSHI2021) [16]; [b]The association of haplotype frequencies with each disease was analyzed using Fisher's exact test with 2×2 contingency tables; [c]P value less than 0.05.